Preoperative Albumin–Bilirubin Grade With Prognostic Nutritional Index Predicts the Outcome of Patients With Early-Stage Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation

Jingying Pan, Shuochun Chen, Guo Tian and Tianan Jiang*

Department of Ultrasound, The First Affiliated Hospital of Zhejiang University, Hangzhou, China

Background: Prognostic nutritional index (PNI) that was designed to assess the nutritional and immunological status of patients and albumin–bilirubin (ALBI) grades can be used as an assessment tool for hepatic function. Both nutritional and immunological statuses have been reported to be independent prognostic factors of patients with hepatocellular carcinoma (HCC). This study aimed to investigate whether PNI together with ALBI could be a better predictor in patients with early-stage HCC undergoing radiofrequency ablation (RFA).

Method: The information of 110 patients with newly diagnosed HCC within the Milan criteria receiving RFA as the initial therapy between 2014 and 2015 was retrospectively collected. Pretreatment PNI, ALBI, and PNI-ALBI grades were calculated. Overall survival (OS) and recurrence-free survival (RFS) were estimated by the Kaplan–Meier method, and multivariate analysis was used to identify prognostic factors.

Result: The 1-, 3-, and 5-years OS rates of patients were 80.0, 30.9, and 23.9%, respectively. Multivariate analysis showed that the tumor size [hazard ratio (HR) = 1.966, 95% confidence interval (CI) = 1.091–3.545, P = 0.025], PNI grade (H = 2.558, 95% CI = 1.289–5.078, P = 0.007), and PNI-ALBI grade (HR = 3.876, 95% CI = 1.729–8.690, P = 0.001) were independent risk factors for OS, whereas only the elevated α-fetoprotein (HR = 1.732, 95% CI = 1.003–2.991, P = 0.049) and the size of the tumor (HR = 1.640, 95% CI = 1.015–2.647, P = 0.43) were independent predictors for better RFS.

Conclusion: This study demonstrates that preoperative PNI-ALBI grade is a simple and useful predictor for OS in patients with early-stage HCC after RFA.

Keywords: hepatocellular carcinoma, radiofrequency ablation, prognostic nutritional index, albumin-bilirubin, overall survival
INTRODUCTION

Liver cancer is the sixth most frequent malignancy, ranked as the fifth most common in men, and ninth in women, respectively. It is the fourth leading cause of cancer-related deaths worldwide, next to lung, colorectal, and stomach cancers (1). Hepatocellular carcinoma (HCC) accounts for ~75% of all liver cancers and is the most common primary liver tumor (2).

The main risk factors for HCC include chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), aflatoxin exposure, etc. However, in most cases, particularly in high-risk areas, HCC develops as a sequela to protracted chronic infection with the HBV or HCV, with or without the development of liver cirrhosis (3).

Although there is a significant improvement in the clinical diagnosis and treatment of HCC, however, with the deterioration in the liver function, high recurrence rates, and distant metastasis, the rates of morbidity and mortality of HCC continue to increase (4).

Percutaneous radiofrequency ablation (RFA) is recognized as an important alternative treatment for small HCCs and cases where resection cannot be performed, due to location, tumor size, multimodality, or inadequate function. RFA can cause necrosis of the tissues of hepatic carcinoma by thermal coagulation (5). It was confirmed to be an effective therapy in patients with hepatic cirrhosis and in single HCC ≤5 cm in diameter or up to three HCCs each ≤3 cm or smaller, and there was no significant difference between the survival rate of RFA and surgical resection (6, 7). Thus, the good candidates for RFA are patients with early-stage HCC (single tumor ≤5 cm in diameter, or tumor number ≤3 with the maximum diameter of each ≤3 cm) (8). But if the HCC diameter is larger than 4 cm, it is not considered to be much effective (9). In RFA, a solitary inserted electrode can cause necrosis of an area with a diameter of ≤3 cm and ablate 2-cm tumor completely (10). Also, RFA has effects that are similar to the microwave ablation and cryoablation, but it has become more common because of the prevalence and convenience of the device. However, the methods for assessing the survival outcomes of the postoperative patients were limited.

The assessment of liver function and failure is vital in predicting overall survival (OS) of the patients with HCC. The Child–Pugh (C-P) grade has been widely used in the assessment of preoperative liver function in clinical practice, and it is based on a score derived from five parameters, including conventional liver function tests, extent of ascites, and degree of hepatic encephalopathy. However, the grading of ascites and encephalopathy can be highly subjective, which could introduce confounding evaluation (11, 12). A new model named the albumin–bilirubin (ALBI) grade was first defined by Johnson et al. (13), and it is one of the best indicators of liver function and showed better discriminative performance than C-P grade. A recent study found that the ALBI grade predicted recurrence-free survival (RFS) and OS more accurately than the CP grade in patients with HCC undergoing liver resection with curative intent (14, 15). ALBI was calculated by two objective variables (albumin and bilirubin), and it was used to stratify patients with HCC into three categories of liver function risk. The higher the ALBI grade, the poorer was the patient’s outcome. For the ALBI grade, the following formula was used: ALBI = (log_{10} bilirubin (µmol/L) × 0.66) + (albumin (g/L) × −0.085) (13). ALBI values had three grades. The cutoff points were as follows: grade 0 (< −2.60), grade 1 (−2.60 to ≤ −1.39), and grade 2 (−1.39).

The prognostic nutritional index (PNI) was originally proposed to assess the nutritional status and predict the surgical risk in gastrointestinal surgery patients by Buzby et al. (16), and Onodera et al. corroborated this in 1984 (17). Since then, further function of PNI was investigated, and a large amount of recent studies found this index to be associated with the prognosis of patients with different types of solid tumors, such as lung cancer, gastric cancer, colorectal cancer, and esophageal carcinoma (18–21). In patients with early-stage HCC, increasing evidence shows that PNI is an effective independent factor of the OS after RFA (15). The following formula was used for PNI: serum albumin (g/L) + 0.005 × absolute lymphocyte count (per mm^3) (17). However, the combination of ALBI and PNI, which can evaluate both the nutritional immunological status and hepatic function, has never been applied in the prognosis of the HCC patients. In this study, a new index, the PNI-ALBI grade, was put up, and its prognostic significance in HCC patients was assessed.

PATIENTS AND METHODS

The study was conducted in patients with HCC receiving RFA as initial therapy in the First Affiliated Hospital of Zhejiang University between January 2014 and December 2015.

All early-stage HCC patients during the same period who met the following criteria were included in this retrospective study: (1) early-stage HCC (single tumor ≤5 cm in diameter, or tumor number ≤3, a maximum diameter of each ≤3 cm), (2) no extrahepatic metastasis or major vascular invasion, (3) platelet count >50,000/mm^3, (4) patients who refused surgical treatment, (5) the patients with a pathological diagnosis of...
TABLE 1 | Baseline characteristics of the patients.

| Clinicopathological feature | Number (%) of patients or Mean ± SD |
|-----------------------------|--------------------------------------|
| Age                         |                                      |
| <55 years                   | 43 (39.1%)                           |
| ≥55 years                   | 67 (60.9%)                           |
| Gender                      |                                      |
| Female                      | 18 (16.4%)                           |
| Male                        | 92 (83.6%)                           |
| Family cases                |                                      |
| Yes                         | 16 (14.5%)                           |
| No                          | 96 (85.5%)                           |
| Tumor size                  |                                      |
| >2.5 cm                     | 30 (27.3%)                           |
| ≤2.5 cm                     | 80 (72.7%)                           |
| TNM stage                   |                                      |
| I                           | 112 (93.3%)                          |
| II                          | 8 (6.7%)                             |
| Hypertension                |                                      |
| Yes                         | 21 (19.1%)                           |
| No                          | 89 (80.9%)                           |
| Diabetes mellitus           |                                      |
| Yes                         | 19 (17.3%)                           |
| No                          | 91 (82.7%)                           |
| Ascites                     |                                      |
| Yes                         | 14 (12.7%)                           |
| No                          | 96 (87.3%)                           |
| Splenomegaly                |                                      |
| Yes                         | 79 (71.8%)                           |
| No                          | 31 (27.3%)                           |
| Cirrhosis                   |                                      |
| Yes                         | 80 (72.7%)                           |
| No                          | 30 (27.3%)                           |
| HBsAg                       |                                      |
| Present                     | 101 (91.8%)                          |
| Absent                      | 9 (8.2%)                             |
| AFP (µg/L)                  |                                      |
| Normal                      | 90 (81.8%)                           |
| Abnormal                    | 20 (18.2%)                           |
| ALBI grade                  |                                      |
| 1                           | 54 (49.1%)                           |
| 2                           | 54 (49.1%)                           |
| 3                           | 2 (1.8%)                             |
| PNI                         |                                      |
| >47.2                       | 47 (42.2%)                           |
| ≤47.2                       | 63 (57.3%)                           |
| PNI-ALBI grade              |                                      |
| 0                           | 42 (38.2%)                           |
| 1                           | 68 (61.8%)                           |
| WBC (×10^3/µL)              | 4.39 ± 1.72                          |
| Platelet count (×10^3/µL)   | 106.31 ± 57.46                       |
| Prothrombin time (s)        | 16.02 ± 34.78                        |
| Albumin (g/L)               | 39.06 ± 5.16                         |
| Total bilirubin (µmol/L)    | 19.01 ± 9.48                         |

SD, standard deviation; TNM, tumor-node-metastasis; HBsAg, positive hepatitis B surface antigen; AFP, α-fetoprotein; ALBI, albumin–bilirubin; PNI, prognostic nutritional index; WBC, white blood cell count.

HCC, and (6) patients who had not undergone chemotherapy or other preoperative antitumor treatment before. The patients were excluded if (1) the patient had an acute infection within 2 weeks, (2) presence of other hematological diseases, or (3) incomplete data. A total of 111 patients met the inclusion criteria, and 1 patient was excluded because of incomplete data. Finally, 110 patients were enrolled in this study (Figure 1).

The subsequent clinical parameters recorded were gender; age at diagnosis; size of the tumor; conditions such as diabetes, hypertension, ascites, schistosomiasis, and cirrhosis; and HBV-DNA levels. Besides, the laboratory blood investigations were carried out before RFA, including white blood cell (WBC) count, platelet count, prothrombin time, absolute lymphocyte count, serum albumin, total bilirubin, and serum α-fetoprotein (AFP).

Authors have access to information that could identify individual participants during or after data collection. This study was provided by the Research Ethics Committee of the First Affiliated Hospital of Zhejiang University. Written informed consent was obtained from patients before treatment. The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations.

Statistical Analysis

All statistical analyses were performed using SPSS 21.0 (SPSS Company, Chicago, IL, USA) for Windows. Categorical variables were examined using Fisher exact test. All continuous variables were expressed as the mean ± standard deviation, and the comparison between them was analyzed using the t-test.
Spearman correlation was determined to analyze the correlation between PNI and PNI-ALBI grade. A time-dependent receiver operating characteristic (ROC) curve analysis was used to determine the cutoff values of PNI. In order to assess the ability of different models in predicting postoperative prognosis, our analysis was performed using the c-statistic equivalent to the area under the ROC curve (AUC). The RFS and OS were determined using the Kaplan–Meier method, and comparisons were determined using the log-rank test. The independent risk factors for the RFS and OS were identified using Cox regression analysis. The variables found to be significant ($P < 0.05$) in the univariate analysis were included in the multivariate analysis. A $P < 0.05$ was considered statistically significant.

**RESULTS**

A total of 110 patients were included in this study. Among them, there were 18 (16.4%) females and 92 (83.6%) males. The average age was 57.38 ±10.10 years. Sixteen (14.5%) patients had similar cases in their families. According to tumor–node–metastasis (TNM) staging system, 112 of the cases were stage I, 8 were stage II, and none of them were stage III or IV. There were 21 patients (19.1%) who had hypertension, and 19 (17.3%) had diabetes mellitus. There were 14 (12.7%) patients with ascites and 29 with schistosomiasis. A total of 80 (72.7%) patients had cirrhosis, and 101 patients had a positive HBV-DNA load. The average tumor size was 2.25 ± 0.67 cm. The size of the tumor was between 0.8 and 4.1 cm. Only one patient had HCC ≤1 cm.
Pan et al. Prognosis of Early-Stage Hepatocellular Carcinoma

in diameter, and the nodule was 0.8 cm in diameter. There was one patient with HCC $\geq$4 cm, and the nodule was 4.1 cm. WBC, platelet count, prothrombin time, total bilirubin, and AFP of patients before RFA are shown in Table 1.

Based on ROC curves, the cutoff value of PNI was 47.2 (Figure 2). A PNI $\geq$47.2 was considered as a high PNI, and a PNI $<$ 47.2 was considered as a low PNI.

Patients with a high PNI were allocated a score of 0; otherwise, the patients were allocated a score of 1. Patients with ALBI grade 0 were allocated a score of 0, grade 1 a score of 1, and grade 2 were allocated a score of 2.

The combination of the ALBI and PNI (PNI-ALBI) scores was the summation of the two scores. They ranged from 0 to 3. There were 47 patients with high PNI. The number of patients in ALBI grades 1 and 2 was 54 each. There was only one patient in ALBI grade 3. The PNI-ALBI scores ranged from 0 to 3. The patients with a score of 0 were considered to have a low PNI-ALBI grade (PNI-ALBI grade 0), and the patients with scores of more than 0 were defined as high PNI-ALBI grade (PNI-ALBI grade 1). Among all the patients in this study, 68 (61.8%) patients were reclassified into PNI-ALBI grade 1, and 42 (38.2%) were into PNI-ALBI grade 0. Spearman correlation was performed.
to find that PNI was highly correlated with PNI-ALBI grade ($r = 0.814, P < 0.01$).

### Analyses for OS

The mean follow-up time was 47.5 ±14.8 months, and in between, 45 (40.9%) patients died. The 1-, 3-, and 5-years OS rates of patients were 80.0, 30.9, and 23.9%, respectively (Figure 3A).

As shown in Table 2, the univariate analysis showed potential association of OS with the following parameters: tumor size [HR = 2.524, 95% confidence interval (CI) = 1.387–4.593, $P = 0.003$], schistosomiasis (HR = 1.937, 95% CI = 0.902–4.161, $P = 0.040$), high AFP level (HR = 1.924, 95% CI = 0.993–3.729, $P = 0.050$), ALBI grade (HR = 2.447, 95% CI = 1.301–4.604, $P = 0.006$), PNI grade (HR = 2.778, 95% CI = 1.406–5.488, $P = 0.003$), and PNI-ALBI grade (HR = 3.876, 95% CI = 1.792–8.690, $P = 0.001$). The result is shown in the CI chart (Figure 4A).

However, in the multivariate analysis, only tumor size (HR = 1.966, 95% CI = 1.091–3.545, $P = 0.025$), PNI (HR = 2.558, 95% CI = 1.289–5.078, $P = 0.007$), and PNI-ALBI grade (HR = 3.876, 95% CI = 1.729–8.690, $P = 0.001$) were independent risk factors for OS (Figure 4B). It confirmed that the PNI-ALBI grade was a strong predictor of OS. The predictive abilities for OS of PNI-ALBI, ALBI, and PNI were compared.

Based on the ROC curves, the AUC of PNI-ALBI grade was 0.676, PNI grade was 0.655, and ALBI grade was 0.652. The PNI-ALBI had the highest AUC, which indicated that the PNI-ALBI might be a better factor to predict the OS of the patients with HCC after RFA (Figure 5A).

### Analyses for RFS

There were 82 (74.5%) patients who suffered from recurrence during the follow-up periods. The 1-, 3-, and 5-years RFS rates were 63.6, 53.2, and 35.0%, respectively (Figure 3B). The univariate Cox proportional hazards model showed that tumor size (HR = 1.808, 95% CI = 1.135–2.882, $P = 0.013$), schistosomiasis (HR = 1.713, 95% CI = 1.014–2.895, $P = 0.044$), AFP (HR = 1.962, 95% CI = 1.152–3.342, $P = 0.013$), and PNI-ALBI grade (HR = 1.647, 95% CI = 1.043–2.600, $P = 0.032$) were independent risk factors for RFS, as shown in Table 3. But in multivariate Cox proportional hazards model, only the AFP (HR = 1.732, 95% CI = 1.003–2.991, $P = 0.049$) and the size of tumor (HR = 1.640, 95% CI = 1.015–2.647, $P = 0.43$) turned out to be independent predictors for better RFS (Figures 4C,D).

Based on the ROC curves, the AUC of PNI-ALBI grade was 0.609, PNI was 0.590, and ALBI grade was 0.597 (Figure 5B). For predicting postoperative RFS, the PNI-ALBI grade had the highest AUC, followed by ALBI grade and PNI.

### The Difference Between the Patients With Low and High PNI-ALBI Grade

As shown in Figure 6A, the 1-, 3-, and 5-years OS rates were 93.3, 82.8, and 79.9%, respectively, for patients with low PNI-ALBI grade. For patients with high PNI-ALBI grade, they were 71.1, 39.6, and 33.5%, respectively, and the difference was statistically significant ($P < 0.001$). As shown in Figure 6B, the 1-, 3-, and 5-years RFS rates for patients with low PNI-ALBI grade were 80.0, 52.2, and 41.4%, respectively; and 58.8, 23.1, and 17.3%, respectively, for patients with high PNI-ALBI grade ($P < 0.001$).

We compared the clinicopathological characteristics of patients with different PNI-ALBI grades (Table 4). Patients with high PNI-ALBI grade had a higher incidence of larger tumor size ($\geq 2.5 \text{ cm}$), ascites, splenomegaly, cirrhosis, AFP, lower albumin, and higher total bilirubin compared with low PNI-ALBI grade.

### DISCUSSION

HCC ranks third in the cancer-related causes of the deaths worldwide (22). Ablation is the recommended treatment for early HCC, and RFA is the most mature and widely used treatment among them (23). It is recommended as the first-line therapy for HCC <3 cm in diameter, as it has a similar survival outcome compared with surgical resection (24). Because of the metabolic function of the liver, the PNI, which was initially designed to evaluate the immunological and nutritional status of patients after surgery of the gastrointestinal tract, was applied in patients with HCC and turned out to be an independent predictor of OS (15, 25–27). Patients with a lower PNI tend to have a worse OS. Low PNI may be caused by hypoalbuminemia and/or lymphocytopenia. The question arises: How do hypoalbuminemia and lymphocytopenia contribute to tumor development and progression? Lymphocytes are important in the adaptive immune system that acts against cancer. They are the cellular foundation for cancer immnosurveillance and immunoediting, and a previous study had proven that a higher lymphocyte count could guarantee an effective antitumor cellular immune response. Likewise, a lower lymphocyte count might weaken the antitumor immune defense, indicating a poor prognosis (28). Hypoalbuminemia in patients with HCC is caused by an impaired liver function due to the underlying chronic liver disease and is also associated with a sustained systemic inflammatory response, either as a host reaction or from the tumor itself.

Rather than advanced-stage diseases, PNI was a better prognostic predictor in patients with an early stage (29), and all the patients in our study were in the early stage. A previous study found that ALBI grade, known as a new assessment method for the hepatic function, was proposed, which was reported to be better than CP and Model for End-stage Liver Disease (MELD) scale in the assessment ability for hepatic function (30). The MELD score was calculated by three objective variables, which were total bilirubin, creatinine, and international normalized ratio (INR). But INR was reported not to sufficiently reflect coagulopathy and consequently liver function in liver cirrhosis (31). The CP score was inferior in terms of stability, because two parameters in the score, namely, ascites and encephalopathy, were variable and were mostly subjective to the observer. In comparison, ALBI grade is a simple and more objective way to assess liver function and therefore could be a better tool in the evaluation of patients with HCC (32). HCC patients with relatively well-preserved hepatic function are more likely to receive appropriate
### TABLE 3 | Univariate and multivariate analyses of baseline prognosticators for recurrence-free survival in patients with early-stage HCC after RFA.

| Variables                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR (95% CI)         | P-value               | HR (95% CI)            | P-value   |
| Age (<55/≥55)                    | 0.908 (0.581–1.418) | 0.671                 | 1.640 (1.015–2.647)    | 0.43      |
| Gender (female/male)             | 1.068 (0.578–1.974) | 0.833                 |                         |           |
| Family cases (yes/no)            | 0.708 (0.390–1.283) | 0.254                 |                         |           |
| Tumor size (>2.5/≤2.5 cm)        | 1.808 (1.135–2.882) | 0.013                 | 1.640 (1.015–2.647)    | 0.43      |
| TNM stage (I/II)                 | 0.517 (0.249–1.075) | 0.077                 |                         |           |
| Hypertension (yes/no)            | 0.900 (0.543–1.490) | 0.681                 |                         |           |
| Diabetes mellitus (yes/no)       | 0.951 (0.526–1.721) | 0.868                 |                         |           |
| Ascites                          | 1.135 (0.601–2.145) | 0.696                 |                         |           |
| Schistosomiasis                  | 1.713 (1.014–2.895) | 0.044                 |                         |           |
| Cirrhosis                        | 1.682 (0.929–3.046) | 0.086                 |                         |           |
| HBsAg (+/−)                      | 1.668 (0.726–3.833) | 0.228                 |                         |           |
| AFP (µg/L) (>200/<200)           | 1.962 (1.152–3.342) | 0.013                 | 1.732 (1.003–2.991)    | 0.049     |
| ALBI grade (1/2,3)               | 1.457 (0.942–2.066) | 0.091                 |                         |           |
| PNI (≥47.2/<47.2)                | 1.587 (1.012–2.488) | 0.044                 |                         |           |
| PNI-ALBI grade (0, 1)            | 1.647 (1.043–2.600) | 0.032                 |                         |           |

HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; HR, hazard ratio; CI, confidence interval; TNM, tumor–node–metastasis; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; PNI, prognostic nutritional index; ALBI, albumin–bilirubin.

**FIGURE 6** | Comparison of Kaplan-Meier overall (A) and recurrence-free (B) survival curves for early stage HCC patients with different PNI-ALBI grade. PNI, prognostic nutritional index; ALBI, albumin–bilirubin; HCC, hepatocellular carcinoma.

therapy, and poor liver function is associated with increased treatment-related toxicity and inferior survival. Also, patients with better liver function can recover faster with fewer complications (33). More and more studies confirmed that ALBI grade is an independent predictor of OS in patients with HCC (34, 35).

It is hypothesized that the combination of PNI and ALBI would increase the accuracy of prognostic evaluation after RFA for HCC, as the combination could evaluate both the nutritional status and the hepatic function of patients with HCC. In this retrospective study, 110 patients with newly diagnosed HCC were included, and all the patients received the RFA. The multivariate analysis and univariate analysis results showed that the PNI-ALBI grade was an independent influencing factor for the OS of the patients with HCC after RFA. More importantly, the performance of PNI-ALBI grade in predicting OS of the HCC patients was better than PNI or ALBI alone. Patients with high PNI-ALBI grades were more likely to have a worse OS. But for RFS, the univariate analysis found that the AFP and PNI-ALBI grade seems to be a predictor; however, in multivariate analysis, the prognostic values of the ALBI and PNI for RFS are uncertain in patients with early-stage HCC receiving RFA as initial therapy. Okamura et al. found the PNI predicts only OS and not RFS in HCC patients after hepatectomy (36). Chu et al. also demonstrated that an elevated AFP level of ≥200 ng/mL was a significant factor associated with RFS by univariate and
TABLE 4 | Comparison of clinicopathologic characteristics between patients with low PNI-ALBI grade and high PNI-ALBI grade.

| Clinicopathological feature | Low PNI-ALBI grade | High PNI-ALBI grade | P-value |
|-----------------------------|--------------------|---------------------|---------|
| Age                         |                    |                     |         |
| <55 years                   | 18 (42.9%)         | 25 (36.8%)          | 0.525   |
| ≥55 years                   | 24 (57.1%)         | 43 (63.2%)          |         |
| Gender                      |                    |                     |         |
| Female                      | 5 (11.9%)          | 13 (19.1%)          | 0.320   |
| Male                        | 37 (88.1%)         | 50 (80.9%)          |         |
| Family cases                |                    |                     |         |
| Yes                         | 7 (16.7%)          | 9 (13.2%)           | 0.828   |
| No                          | 35 (83.3%)         | 59 (86.8%)          |         |
| Tumor size                  |                    |                     |         |
| >2.5 cm                     | 6 (14.3%)          | 24 (35.3%)          | 0.016   |
| <2.5 cm                     | 36 (85.7%)         | 44 (64.7%)          |         |
| TNM stage                   |                    |                     |         |
| I                           | 39 (92.9%)         | 63 (92.6%)          | 0.97    |
| II                          | 3 (7.1%)           | 5 (7.4%)            |         |
| Hypertension                |                    |                     |         |
| Yes                         | 10 (23.8%)         | 17 (25.0%)          | 0.538   |
| No                          | 32 (76.2%)         | 51 (75.0%)          |         |
| Diabetes mellitus           |                    |                     |         |
| Yes                         | 9 (21.4%)          | 10 (14.7%)          | 0.439   |
| No                          | 33 (78.6%)         | 58 (85.3%)          |         |
| Ascites                     |                    |                     |         |
| Yes                         | 2 (4.6%)           | 12 (17.6%)          | 0.042   |
| No                          | 40 (95.4%)         | 56 (82.4%)          |         |
| Splenomegaly                |                    |                     |         |
| Yes                         | 19 (45.2%)         | 60 (88.2%)          | <0.001  |
| No                          | 23 (54.8%)         | 8 (11.8%)           |         |
| Cirrhosis                   |                    |                     |         |
| Yes                         | 25 (59.5%)         | 62 (91.2%)          | <0.001  |
| No                          | 27 (40.5%)         | 6 (8.8%)            |         |
| HBsAg                       |                    |                     |         |
| Present                     | 37 (88.1%)         | 63 (92.6%)          | 0.332   |
| Absent                      | 6 (13.9%)          | 5 (7.4%)            |         |
| AFP (µg/L)                  |                    |                     |         |
| Normal                      | 39 (92.9%)         | 51 (75.0%)          | 0.022   |
| Abnormal                    | 3 (7.1%)           | 17 (25.0%)          |         |
| WBC (×10^3/µL)              | 5.09 ± 1.14        | 3.96 ± 1.73         | 0.382   |
| Platelet count (×10^3/µL)   | 136.90 ± 61.03     | 87.41 ± 46.29       | 0.157   |
| Prothrombin time (s)        | 12.10 ± 1.74       | 18.44 ± 44.16       | 0.146   |
| Albumin (g/L)               | 43.74 ± 2.65       | 36.18 ± 4.11        | 0.002   |
| Total bilirubin (µmol/L)    | 15.57 ± 7.62       | 21.12 ± 9.93        | 0.028   |

HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; PNI, prognostic nutritional index; ALBI, albumin–bilirubin.

multivariate analyses, whereas PNI had limited prognostic value for RFS in early-stage HCC patients undergoing RFA (15). However, a study conducted by Chan et al. showed that the PNI could be an important prognostic parameter for HCC patients who underwent hepatectomy (37). Regarding ALBI, several studies have evidenced that it could have a predictive value in OS. But fewer studies were performed to evaluate the predictive role of ALBI in estimating HCC recurrence (38).

No clear explanation for this difference is available at present. Further research with larger sample size and longer follow-up time on this issue may show the PNI and ALBI to be a significant predictor of both OS and RFS. A significant difference in the PNI-ALBI grade was identified in the current univariate analysis for RFS.

Our results indicated that the PNI-ALBI grade could better reflect the long-term survival for patients with HCC after RFA, compared with either score alone. The results of our study can help us to identify patients who had a potentially poor prognosis and take interventions before the RFA.

Although, to our best knowledge, this is the first study to combine PNI and ALBI to evaluate the prognostic value in patients with early-stage HCC after RFA, this study had several potential limitations. First, this was a retrospective study. Second, this was a single-center study, and patients involved were confined to the east of China. Third, the sample size of the study was limited, and a further larger sample size cohort is needed. Fourth, some other well-known indicators, including the platelet-to-lymphocyte ratio, C-reactive protein level, and Glasgow prognostic score, were not evaluated in our cohort, although they have been proposed earlier as prognostic factors for patients with HCC.

In conclusion, this study demonstrated that the PNI-ALBI grade was a more accurate marker for predicting the OS of patients with early-stage HCC treated with RFA in comparison to PNI or ALBI alone. Patients with high PNI-ALBI grade are more likely to have a worse outcome, which suggests that we should check out the patients’ liver function and nutritional status before performing the RFA.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Research Ethics Committee of The First Affiliated Hospital of Zhejiang University. The ethics committee waived the requirement of written informed consent for participation.

AUTHOR CONTRIBUTIONS

JP conceived the study and wrote the manuscript. SC collected the data. JP and GT performed statistical analyses. TJ provided support and helped with manuscript revision. All authors were involved in analyzing the results.

FUNDING

This study was supported by grants from National Key R&D Program of China (No. 2018YFC0114900), the National Natural
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492

2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. (2013) 47:S2–6. doi: 10.1097/MCG.0b013e31828722f9

3. Yang, JD, Hainaut, P, Goeres, GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. (2019) 16:389–604. doi: 10.1038/s41575-019-0186-y

4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. (2009) 27:1485–91. doi: 10.1200/JCO.2008.20.7753

5. Luo W, Zhang Y, He G, Yu M, Zheng M, Liu L, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Oncol. (2017) 15:126. doi: 10.1186/s12957-017-1196-2

6. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. (2003) 228:233–40. doi: 10.1148/radiol.2281020718

7. Fung K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. (2012) 57:794–802. doi: 10.1016/j.jhep.2012.05.007

8. Zhu ZX, Huang JW, Liao MH, Zeng Y. Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Ipn J Clin Oncol. (2016) 46:1075–80. doi: 10.1093/jicço/hyw134

9. Dhir M, Melin AA, Douaizhi J, Lin C, Zhen WK, Hussain SM, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. (2016) 263:1122–25. doi: 10.1097/SLA.0000000000001556

10. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. (2008) 47:82–9. doi: 10.1002/hep.21933

11. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. (2008) 28:110–22. doi: 10.1055/s-2008-1040325

12. Shetty K, Rybicki L, Carey WD. The child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology. (1997) 25:1049–53. doi: 10.1002/hep.510250501

13. Johnson PJ, Berhane S, Kagbehayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. (2015) 33:550–8. doi: 10.1200/JCO.2014.57.9151

14. Johnson PJ, Berhane S, Kagbehayashi C, Satomura S, Teng M, Reeves HL, et al. Prognostic significance of combined albumin–bilirubin and tumor–node–metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma. Hepatol Res. (2015) 45:1289–98. doi: 10.1111/hepr.12868

15. Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, Lu SN, et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. (2018) 8:16611. doi: 10.1038/s41598-018-34543-z

16. Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. (1980) 139:160–7. doi: 10.1016/0002-9610(80)90246-9

17. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. (1984) 85:1001–5.

18. Shimizu K, Okita R, Saiso Y, Yukawa T, Maeda A, Nojima Y, et al. Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer. Ther Clin Risk Manag. (2011) 7:1155–61. doi: 10.2147/TCRM.S92961

19. Nozoe T, Kiyura M, Ishida M, Saeki H, Korenaga D, Sugimachi K. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal cancer. Eur J Surg Oncol. (2002) 28:396–400. doi: 10.1053/ejso.2002.1257

20. Nozoe T, Kohno M, Iuchi T, Mori E, Maeda T, Matsukuma A, et al. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today. (2012) 42:532–5. doi: 10.1007/s00595-011-0616-0

21. Abe A, Kurita K, Hayashi H, Ishihama T, Ueda A. Correlation between prognostic nutritional index and occlusal status in gastric cancer. Oral Dis. (2020) 26:465–72. doi: 10.1111/odi.13242

22. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. (2015) 136:E359–86. doi: 10.1002/ijc.29216

23. Aubé C, Bouvier A, Lebigot J, Vervueren L, Cartier V, Oberti F. Radiological treatment of HCC: interventional radiology at the heart of management. Diagn Interv Imaging. (2015) 96:625–36. doi: 10.1016/j.dii.2015.04.008

24. Maizzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrastine bed of ablation, resection, and transplantation. Semin Liver Dis. (2014) 34:413–26. doi: 10.1055/s-0034-1394365

25. Ke M, Xu T, Li N, Ren Y, Shi A, Lv Y, et al. Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria. Oncotarget. (2016) 7:81611–20. doi: 10.18632/oncotarget.13151

26. Ji F, Liang Y, Fu S, Chen D, Cai X, Li S, et al. Prognostic value of combined preoperative prognostic nutritional index and body mass index in HCC after hepatectomy. HPB. (2017) 9:695–705. doi: 10.1016/j.hpb.2017.04.008

27. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. (2012) 106:1439–45. doi: 10.1038/bjc.2012.92

28. Hoffmann TK, Dовораки G, Тукхи Cor, M, Edenbauer G, Gooding W, Johnston JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. (2002) 8:2553–62.

29. Okamura Y, Sugita T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The optimal cutoff value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma. Surg Today. (2017) 47:986–93. doi: 10.1007/s00595-017-1491-0

30. Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itoyabashi E, et al. Albumin–Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and child-Pugh classifications. Liver Cancer. (2017) 6:204–15. doi: 10.1159/000452846

31. Bedrelli S, Sowa JP, Gerken G, Saner FH, Canbay A. Management of acute-on-chronic liver failure: rotational thromboelastometry may reduce
substitution of coagulation factors in liver cirrhosis. *Gut.* (2016) 65:357–8. doi: 10.1136/gutjnl-2015-309922

32. Peng Y, Qi X, Guo X. Child-pugh versus meld score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. *Medicine.* (2016) 95:e2877. doi: 10.1097/MD.0000000000002877

33. Zou H, Yang X, Li QL, Zhou QX, Xiong J, Wen Y. A comparative study of albumin-bilirubin score with child-pugh score, model for end-stage liver disease score and indocyanine green R15 in predicting posthepatectomy liver failure for hepatocellular carcinoma patients. *Digest Dis.* (2018) 36:236–43. doi: 10.1159/000486590

34. Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Huang YH. An Albumin-Bilirubin (ALBI) grade-based prognostic model for patients with hepatocellular carcinoma within Milan criteria. *Am J Clin Oncol.* (2019) 42:698–704. doi: 10.1097/COC.0000000000000531

35. Nguyen TTH, Nguyen VH, Nguyen VH, Nguyen TL, Le VQ. Role of baseline albumin-bilirubin grade on predict overall survival among sorafenib-treated patients with hepatocellular carcinoma in Vietnam. *Cancer Control.* (2019) 26:1073274819865269. doi: 10.1177/1073274819865269

36. Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after heptatectomy for hepatocellular carcinoma. *World J Surg.* (2015) 39:1501–9. doi: 10.1007/s00268-015-2982-z

37. Chan AW, Chan SL, Wong GL, Wong VW, Chong CC, Lai PB, et al. Prognostic Nutritional Index (PNI) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection. *Ann Surg Oncol.* (2015) 22:4038–48. doi: 10.1245/s10434-015-4516-1

38. Peng Y, Wei Q, He Y, Xie Q, Liang Y, Zhang L, et al. ALBI versus child-pugh in predicting outcome of patients with HCC: a systematic review. *Expert Rev Gastroenterol Hepatol.* (2020) 14:383–400. doi: 10.1080/17474124.2020.1748010

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Pan, Chen, Tian and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.